Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

PALI

Live52w high -36.6%

Annual Quarterly

Core line items from PALI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: PALISADE BIO, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-14.86M	$-11.48M	$-7.88M	$-3.67M
Net Income	Not available	$-14.44M	$-11.09M	$-7.61M	$-3.53M
EPS (Diluted)	$-0.05	$-10.19	$-9.50	$-7.60	$-4.59
Total Assets	Not available	$10.88M	$9.34M	$12.87M	$12.65M
Total Liabilities	Not available	$3.39M	$2.73M	$2.92M	$2.59M
Cash & Equivalents	Not available	$9.82M	$8.04M	$11.35M	$11.28M
Free Cash Flow OCF − CapEx	Not available	$-12.19M	$-9.81M	$-6.68M	Not available
Shares Outstanding	Not available	2.77M	1.20M	966.35K	851.30K

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from PALI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -36.6%

Entity: PALISADE BIO, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-14.86M	$-11.48M	$-7.88M	$-3.67M
Net Income	Not available	$-14.44M	$-11.09M	$-7.61M	$-3.53M
EPS (Diluted)	$-0.05	$-10.19	$-9.50	$-7.60	$-4.59
Total Assets	Not available	$10.88M	$9.34M	$12.87M	$12.65M
Total Liabilities	Not available	$3.39M	$2.73M	$2.92M	$2.59M
Cash & Equivalents	Not available	$9.82M	$8.04M	$11.35M	$11.28M
Free Cash Flow OCF − CapEx	Not available	$-12.19M	$-9.81M	$-6.68M	Not available
Shares Outstanding	Not available	2.77M	1.20M	966.35K	851.30K

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.